RhumbLine Advisers’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Hold |
0
| – | – | – | 4090 |
|
|
2025
Q4 | – | Hold |
0
| – | – | – | 4128 |
|
|
2025
Q3 | – | Hold |
0
| – | – | – | 4114 |
|
|
2025
Q2 | – | Sell |
-137,230
| Closed | -$88.9K | – | 4209 |
|
|
2025
Q1 | $63.3K | Sell |
137,230
-15,921
| -10% | -$10K | ﹤0.01% | 3521 |
|
|
2024
Q4 | $113K | Buy |
153,151
+7,212
| +5% | +$8.69K | ﹤0.01% | 3443 |
|
|
2024
Q3 | $229K | Sell |
145,939
-6,846
| -4% | -$12.2K | ﹤0.01% | 3168 |
|
|
2024
Q2 | $257K | Buy |
152,785
+17,940
| +13% | +$32.2K | ﹤0.01% | 3083 |
|
|
2024
Q1 | $324K | Buy |
134,845
+4,554
| +3% | +$9.78K | ﹤0.01% | 2941 |
|
|
2023
Q4 | $199K | Hold |
130,291
| – | – | ﹤0.01% | 3190 |
|
|
2023
Q3 | $142K | Sell |
130,291
-9,456
| -7% | -$16.6K | ﹤0.01% | 3336 |
|
|
2023
Q2 | $320K | Buy |
139,747
+14,681
| +12% | +$39K | ﹤0.01% | 2965 |
|
|
2023
Q1 | $304K | Buy |
125,066
+5,949
| +5% | +$13.6K | ﹤0.01% | 2610 |
|
|
2022
Q4 | $228K | Buy |
119,117
+5,722
| +5% | +$12.2K | ﹤0.01% | 2764 |
|
|
2022
Q3 | $272K | Buy |
113,395
+15,925
| +16% | +$44.1K | ﹤0.01% | 2758 |
|
|
2022
Q2 | $181K | Buy |
97,470
+17,536
| +22% | +$33.5K | ﹤0.01% | 2956 |
|
|
2022
Q1 | $167K | Sell |
79,934
-6,726
| -8% | -$18.6K | ﹤0.01% | 2794 |
|
|
2021
Q4 | $341K | Buy |
86,660
+2,669
| +3% | +$13K | ﹤0.01% | 2667 |
|
|
2021
Q3 | $404K | Buy |
83,991
+2,199
| +3% | +$9.03K | ﹤0.01% | 2639 |
|
|
2021
Q2 | $375K | Buy |
81,792
+26,714
| +49% | +$129K | ﹤0.01% | 2691 |
|
|
2021
Q1 | $323K | Sell |
55,078
-1,611
| -3% | -$11.2K | ﹤0.01% | 2678 |
|
|
2020
Q4 | $194K | Buy |
56,689
+6,530
| +13% | +$12.5K | ﹤0.01% | 2848 |
|
|
2020
Q3 | $72K | Sell |
50,159
-14,727
| -23% | -$26.2K | ﹤0.01% | 2925 |
|
|
2020
Q2 | $129K | Buy |
64,886
+8,279
| +15% | +$16.2K | ﹤0.01% | 2910 |
|
|
2020
Q1 | $110K | Sell |
56,607
-3,500
| -6% | -$10.4K | ﹤0.01% | 2757 |
|
|
2019
Q4 | $249K | Buy |
60,107
+1,359
| +2% | +$5.23K | ﹤0.01% | 2678 |
|
|
2019
Q3 | $177K | Sell |
58,748
-400
| -0.7% | -$1.24K | ﹤0.01% | 2774 |
|
|
2019
Q2 | $372K | Buy |
59,148
+3,617
| +7% | +$21.7K | ﹤0.01% | 2494 |
|
|
2019
Q1 | $309K | Sell |
55,531
-1,662
| -3% | -$10.1K | ﹤0.01% | 2538 |
|
|
2018
Q4 | $380K | Buy |
57,193
+18,376
| +47% | +$149K | ﹤0.01% | 2422 |
|
|
2018
Q3 | $414K | Sell |
38,817
-2,780
| -7% | -$31.9K | ﹤0.01% | 2354 |
|
|
2018
Q2 | $499K | Buy |
41,597
+1,354
| +3% | +$13.8K | ﹤0.01% | 2318 |
|
|
2018
Q1 | $345K | Sell |
40,243
-1,375
| -3% | -$12.7K | ﹤0.01% | 2371 |
|
|
2017
Q4 | $411K | Sell |
41,618
-9,173
| -18% | -$95.3K | ﹤0.01% | 2318 |
|
|
2017
Q3 | $624K | Buy |
50,791
+1,260
| +3% | +$18.6K | ﹤0.01% | 2204 |
|
|
2017
Q2 | $815K | Buy |
49,531
+2,005
| +4% | +$31K | ﹤0.01% | 2051 |
|
|
2017
Q1 | $682K | Buy |
47,526
+1,281
| +3% | +$19K | ﹤0.01% | 2117 |
|
|
2016
Q4 | $640K | Buy |
46,245
+3,568
| +8% | +$57.2K | ﹤0.01% | 2103 |
|
|
2016
Q3 | $771K | Buy |
42,677
+700
| +2% | +$11.3K | ﹤0.01% | 1960 |
|
|
2016
Q2 | $602K | Sell |
41,977
-10,926
| -21% | -$148K | ﹤0.01% | 2085 |
|
|
2016
Q1 | $632K | Buy |
52,903
+3,455
| +7% | +$36.2K | ﹤0.01% | 2057 |
|
|
2015
Q4 | $658K | Buy |
49,448
+1,725
| +4% | +$21.2K | ﹤0.01% | 2075 |
|
|
2015
Q3 | $513K | Buy |
47,723
+916
| +2% | +$10K | ﹤0.01% | 2211 |
|
|
2015
Q2 | $377K | Buy |
46,807
+8,989
| +24% | +$66K | ﹤0.01% | 2513 |
|
|
2015
Q1 | $250K | Buy |
37,818
+6,715
| +22% | +$45.9K | ﹤0.01% | 2708 |
|
|
2014
Q4 | $198K | Buy |
31,103
+1,139
| +4% | +$9.18K | ﹤0.01% | 2817 |
|
|
2014
Q3 | $296K | Sell |
29,964
-14
| -0% | -$149 | ﹤0.01% | 2525 |
|
|
2014
Q2 | $338K | Sell |
29,978
-197
| -0.7% | -$2.12K | ﹤0.01% | 2519 |
|
|
2014
Q1 | $365K | Sell |
30,175
-1,583
| -5% | -$20.2K | ﹤0.01% | 2412 |
|
|
2013
Q4 | $400K | Sell |
31,758
-914
| -3% | -$14.5K | ﹤0.01% | 2392 |
|
|
2013
Q3 | $542K | Buy |
32,672
+424
| +1% | +$7.11K | ﹤0.01% | 2160 |
|
|
2013
Q2 | $490K | Buy |
+32,248
| New | +$490K | ﹤0.01% | 2271 |
|
Other funds holding LXRX
AG
SL
SC
VCM
RhumbLine Advisers's LXRX Position: Q1 2026 in Review
RhumbLine Advisers held its Lexicon Pharmaceuticals (LXRX) position steady in Q1 2026 at 0 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #4090.
RhumbLine Advisers first reported a position in LXRX in Q2 2013 and has held it in 48 quarters since. The position peaked at $815K in Q2 2017. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.
- RhumbLine Advisers held 0 shares of Lexicon Pharmaceuticals worth $2 as of Q1 2026.
- RhumbLine Advisers left its Lexicon Pharmaceuticals share count unchanged in Q1 2026.
- Lexicon Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #4090 holding.
- RhumbLine Advisers first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
- RhumbLine Advisers's Lexicon Pharmaceuticals position peaked at $815K in Q2 2017.
- 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.